ECG

Masimo W1™ Medical Watch Receives FDA 510(k) Clearance for Over-the-Counter and Prescription Use

Retrieved on: 
Friday, November 17, 2023
Pharmaceutical, Health, FDA, Medical Devices, Consumer Electronics, Health Technology, Wearables, Mobile Technology, Technology, ECG, Empowerment, COPD, MASI, Virtual Health Library, Pulse, Patient, Multimedia, Algorithm, Heart rate, Anesthesiology, CHUV, Hospital, PR, Oxygen saturation (medicine), CHF, OTC, Physiology, Medical imaging, Masimo

Masimo (NASDAQ: MASI) today announced that the Masimo W1™ medical watch has received FDA 510(k) clearance for over-the-counter (OTC) and prescription use (Rx).

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that the Masimo W1™ medical watch has received FDA 510(k) clearance for over-the-counter (OTC) and prescription use (Rx).
  • The FDA clearance expands the indications for the Masimo W1 in the U.S. as a medical device for use by adults in hospitals, clinics, long-term care facilities, and in the home.
  • The continuous data from the Masimo MW-1 module is displayed in real-time on the Masimo W1 watch touchscreen in an easy-to-interpret format.
  • The Masimo W1 and the integrated Masimo MW-1 Module are indicated for adults in hospitals, clinics, long-term care facilities, and homes.

SDC Announces Partnership with CRIO on eSource Initiative

Retrieved on: 
Tuesday, November 14, 2023
Data Management, Health, Technology, Health Technology, Software, Clinical Trials, ECG, SDC, Clinical trial, Data management, CRIO, Patient, Multimedia, ESourcing Capability Model, Fujitsu Technology Solutions, EDC, Calendar, CFR

Continuing the momentum of technology solution innovations after its recent release of SDC InsightsTM, SDC is proud to partner with CRIO to bring eSource functionality in-house to better serve clients and their clinical needs.

Key Points: 
  • Continuing the momentum of technology solution innovations after its recent release of SDC InsightsTM, SDC is proud to partner with CRIO to bring eSource functionality in-house to better serve clients and their clinical needs.
  • View the full release here: https://www.businesswire.com/news/home/20231114143441/en/
    “With SDC’s in-house developers, we can efficiently meet the individual needs of each protocol with CRIO eSource, a compliant solution that harnesses real-time data to streamline clinical compliance and reduce transcription errors” says Quan Doan, Vice President, Technology Solutions.
  • SDC’s eSource solution, powered by CRIO, is a comprehensive, 21 CFR Part 11 compliant system that enables staff to capture data in real-time.
  • SDC also just launched SDC Capture™ -- ePRO technology to ensure an optimized user experience for clients and sites with superior data reliability and robust data security.

Vital Signs Monitoring Capabilities Get a Boost Thanks to ams OSRAM’s Ultra-low Noise AFE Sensor Technology for Wearables

Retrieved on: 
Monday, November 13, 2023
Software, Hardware, Health, Consumer Electronics, Health Technology, Wearables, Mobile Technology, Technology, Semiconductor, Light-emitting diode, ECG, AMS, AFE, Signal-to-noise ratio, Acquisition, Spacecraft, OSRAM, Ams-OSRAM, LED, Algorithm, WLCSP, Heart rate, PPG, Body composition, Oxygen saturation (medicine), Noise, Vital signs, Temperature, Blood pressure, Television, Medical imaging

The AS7058’s ultra-low noise characteristics produce a very high optical signal-to-noise ratio of 120dB.

Key Points: 
  • The AS7058’s ultra-low noise characteristics produce a very high optical signal-to-noise ratio of 120dB.
  • ams OSRAM products for vital signs monitoring include LEDs, photodiodes and temperature sensors as well as the AS705x series of AFEs.
  • ams OSRAM also supplies a complete hardware demonstration system for vital signs monitoring in a smart watch form factor.
  • For more technical information or for sample requests, go to ams AS7058 High Performance Vital Sign and ams AS7058_EVM_EB Evaluation Kit .

Global Holter Monitor Market Insights Report 2023: Market was Valued at $742.61 Million in 2023 and is Expected to Reach $1.20 Billion by 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 10, 2023
Medical Devices, Health, Atrial fibrillation, ECG, Arrhythmia, Prevalence, Holter monitor, Ageing, Growth, Hospital, Pet industry

The "Global Holter Monitor Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Holter Monitor Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.
  • The global Holter Monitor market was valued at $742.61 million in 2023 and is expected to reach $1,208.08 million by 2029, growing at a CAGR of 8.45%.
  • The study considers a detailed scenario of the present global Holter monitor market and its market dynamics for 2024-2029.
  • Among the different channel types, the Holter monitor with three channels dominated the market in 2023, accounting for 49.06% of the market share.

Exciting New Applications of vMap for Ventricular Arrhythmias Highlighted at AHA 2023

Retrieved on: 
Friday, November 10, 2023
Medical Devices, Health, Radiology, Health Technology, Cardiology, ECG, Arrhythmia, Associate, Research, PVC, ICD, Patient, Multimedia, UC San Diego Health, Vector, Ventricular tachycardia, Workflow, Death, VF, Recurrence, Pharmaceutical industry, Science, Medicine

In 32 consecutive VT patients, 26 had unstable VT. All 26 unstable VT patients successfully underwent vMap’s arrhythmia analysis and received guided VT ablation.

Key Points: 
  • In 32 consecutive VT patients, 26 had unstable VT. All 26 unstable VT patients successfully underwent vMap’s arrhythmia analysis and received guided VT ablation.
  • In the second study, “Novel Pre-Operative Non-Invasive Computational 12-Lead ECG Mapping to Facilitate Surgical Ablation of Ventricular Arrhythmias,” Dr. Ho introduces a novel workflow that utilizes pre-operative use of vMap to localize ventricular arrhythmias in patients undergoing cardiac surgery.
  • "These studies exemplify the strides we are taking to advance the care of patients with ventricular arrhythmias.
  • November 12, 2023, 12:30 PM – 12:35 PM, Moderated Digital Posters 4, Science and Technology Hall, Level 2
    November 12, 2023, 3.30 PM – 4.45 PM, Zone 2, Science and Technology Hall, Level 2

Lucem Health Introduces Reveal for Stroke to Accelerate Treatment of AFib-Related Stroke Risks

Retrieved on: 
Wednesday, December 13, 2023
ECG, Risk, Arrhythmia, Ad Lucem, Patient, FDA, Atrial flutter, American Heart Association, Bleeding, Pharmaceutical industry, Stroke, Ventricular fibrillation

DAVIDSON, N.C., Dec. 13, 2023 /PRNewswire/ -- Lucem Health™, a leader in AI-driven early disease detection solutions, announced today the release of Reveal for Stroke, an innovative solution designed to identify patients with undocumented atrial fibrillation (AFib) and higher risk of AFib-related strokes. As noted by the American Heart Association, AFib affects 2.7-6.1 million individuals in the US and significantly increases the risk of ischemic stroke. Thus, the need for early identification and intervention has never been more critical.

Key Points: 
  • However, at least one-in-five AFib cases remain undocumented in clinical practice, leading to many patients missing out on important stroke prevention treatment.
  • "At Lucem Health, we develop solutions that identify patients with major health risks that are hiding in plain sight.
  • Lucem Health has partnered with AccurKardia, a renowned ECG-led diagnostics company, to develop Reveal for Stroke.
  • "Reveal for Stroke represents a shared vision with Lucem Health to harness the full potential of ECG data in managing stroke risks.

Lucem Health Introduces Reveal for Stroke to Accelerate Treatment of AFib-Related Stroke Risks

Retrieved on: 
Wednesday, December 13, 2023
ECG, Risk, Arrhythmia, Ad Lucem, Patient, FDA, Atrial flutter, American Heart Association, Bleeding, Pharmaceutical industry, Stroke, Ventricular fibrillation

DAVIDSON, N.C., Dec. 13, 2023 /PRNewswire/ -- Lucem Health™, a leader in AI-driven early disease detection solutions, announced today the release of Reveal for Stroke, an innovative solution designed to identify patients with undocumented atrial fibrillation (AFib) and higher risk of AFib-related strokes. As noted by the American Heart Association, AFib affects 2.7-6.1 million individuals in the US and significantly increases the risk of ischemic stroke. Thus, the need for early identification and intervention has never been more critical.

Key Points: 
  • However, at least one-in-five AFib cases remain undocumented in clinical practice, leading to many patients missing out on important stroke prevention treatment.
  • "At Lucem Health, we develop solutions that identify patients with major health risks that are hiding in plain sight.
  • Lucem Health has partnered with AccurKardia, a renowned ECG-led diagnostics company, to develop Reveal for Stroke.
  • "Reveal for Stroke represents a shared vision with Lucem Health to harness the full potential of ECG data in managing stroke risks.

CathVision Unveils ECGenius 3.1 To Improve Workflows and Optimize EGM AI Analyses

Retrieved on: 
Tuesday, December 12, 2023
NYU Langone Health, ECG, Acquisition, Q3, Signal, PVI, Algorithm, Workflow, Intelligence, Software, Diagnosis, AI, Physician, Noise, EP, Medical imaging, Electrophysiology

COPENHAGEN, Denmark, Dec. 12, 2023 /PRNewswire/ -- CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the launch of ECGenius 3.1, an advanced version of the ECGenius™ System software. The new version improves workflow and streamlines processes to accelerate adoption as electrophysiologists integrate AI analyses into the EP lab, increasing the demand for high-quality signal data.1

Key Points: 
  • The new version improves workflow and streamlines processes to accelerate adoption as electrophysiologists integrate AI analyses into the EP lab, increasing the demand for high-quality signal data.1
    Intelligent automated analyses can effectively enable physicians to confirm the success of ablation efforts.
  • ECGenius 3.1 delivers several new and enhanced features to provide an improved user experience throughout, including:
    The release of ECGenius 3.1 follows the Q3 launch of the PVI Analyzer™ and Signal Complexity™ algorithms.
  • ECGenius 3.1 makes the workflow transition seamless and strengthens our leadership position in equipping electrophysiologists with the technology necessary to elevate patient outcomes."
  • With exceptional data from the ECGenius System, intelligent automated analyses can effectively enable physicians to confirm the success of ablation efforts.

Biobeat Wearables for Enhanced Remote Patient Monitoring Partners with Best Buy Health's Care at Home Platform, Current Health

Retrieved on: 
Monday, December 11, 2023
ECG, Best Buy, Entrepreneurship, RPM, Respiratory rate, Patient, Stroke, Health, Wrist, Cardiac output, Vital signs

PETAH TIKVA, Israel, Dec. 11, 2023 /PRNewswire/ -- Biobeat , a global leader in wearable remote patient monitoring (RPM) solutions for the healthcare continuum, today announced its plans to integrate with Best Buy Health's care at home platform Current Health .

Key Points: 
  • PETAH TIKVA, Israel, Dec. 11, 2023 /PRNewswire/ -- Biobeat , a global leader in wearable remote patient monitoring (RPM) solutions for the healthcare continuum, today announced its plans to integrate with Best Buy Health's care at home platform Current Health .
  • Biobeat's wrist and chest monitors will be featured as one of the technology solutions for healthcare organizations utilizing Current Health to scale their care at home capabilities.
  • "Technology is a crucial component of delivering care to patients and improving their experiences and outcomes," states Chris McGhee, CEO of Current Health.
  • "We are excited to continuously improve our remote patient monitoring offering to make receiving care in the home a simplified experience for patients and providers."

Global Wearable Patches Market Analysis Report 2023: Market to Exceed $26.8 Billion by 2031 - AI Algorithms for Wearable Patches for Better Clinical Outcome Presents Unique Opportunities

Retrieved on: 
Friday, December 8, 2023
ECG, Migraine, Nursing, T1D, Abbott Laboratories, Food, Prevalence, Ageing, AID, MDR, Laboratory, Stroke, Continuous glucose monitor, FDA, Heart rate, Region, CE, Conditional sentence, Clothing, Diabetes, Software, Diagnosis, Communication, Growth, Medicare, Hyperglycemia, FreeStyle, Hospital, Skin, Continuous monitoring, GlySens ICGM, Temperature, Hypoglycemia, Blood pressure, Beauty salon, Medical device, Pharmaceutical industry

The global wearable patches market was valued at $10,462.4 million in 2022 and is expected to reach $26,892.7 million by 2031, growing at a CAGR of 10.19% between 2023 and 2031.

Key Points: 
  • The global wearable patches market was valued at $10,462.4 million in 2022 and is expected to reach $26,892.7 million by 2031, growing at a CAGR of 10.19% between 2023 and 2031.
  • The top segment players who are leading include manufacturers of different kinds of wearable medical patches.
  • The blood glucose patches captured around 82.23% of the presence in the market in 2022.
  • Patches such as blood glucose patches, heart rate and ECG patches, temperature patches, and others are used for monitoring and diagnosis of various conditions.